Defect in the ATP13A2 Gene Can Lead to Parkinson’s

Location:Homepage > About Us > Blogs >

Defect in the ATP13A2 Gene Can Lead to Parkinson’s

Researchers at KU Leuven have discovered that a defect in the ATP13A2 gene causes cell death by disrupting the cellular transport of polyamines. When this happens in the part of the brain that controls body movement, it can lead to Parkinson's disease.

With more than six million patients around the world, Parkinson's disease is one of the most common neurodegenerative disorders. Around twenty genetic defects have already been linked to the disease, but for several of these genes, we don't know what function they fulfill. The ATP13A2 gene used to be one of these genes, but researchers at KU Leuven have now discovered its function in the cell. The researchers explain how a defect in the gene can cause Parkinson's disease in their article "ATP13A2 deficiency disrupts lysosomal polyamine export" published in Nature.

"We found that ATP13A2 transports polyamines and is crucial for their uptake into the cell," explains senior author Peter Vangheluwe, PhD, from the Laboratory of Cellular Transport Systems. "Polyamines are essential molecules that support many cell functions and protect cells in stress conditions. But how polyamines are taken up and transported in human cells was still a mystery. Our study reveals that ATP13A2 plays a vital role in that process. Our experiments showed that polyamines enter the cell via lysosomes and that ATP13A2 transfers polyamines from the lysosome to the cell interior. This transport process is essential for lysosomes to function properly as the "waste disposal system" of the cell where obsolete cell material is broken down and recycled. However, mutations in the ATP13A2 gene disrupt this transport process, so that polyamines build up in lysosomes. As a result, the lysosomes swell and eventually burst, causing the cells to die. When this happens in the part of the brain that controls body movement, this process may trigger the motion problems and tremors related to Parkinson's disease.

Unraveling the role of ATP13A2 is an important step forward in Parkinson's research and sheds new light on what causes the disease, but a lot of work remains to be done.

Vangheluwe continues:"We now have to investigate how deficient polyamine transport is linked to other defects in Parkinson's disease such as the accumulation of plaques in the brain and malfunctioning of the mitochondria, the 'energy factories' of the cell. We need to examine how these mechanisms influence each other," he says. "The discovery of the polyamine transport system in animals has implications beyond Parkinson's disease as well, because polyamine transporters also play a role in other age-related conditions, including cancer, cardiovascular diseases, and several neurological disorders. Now that we have unraveled the role of ATP13A2, we can start searching for molecules that influence its function. Our lab is already collaborating with the Centre for Drug Design and Discovery-a tech transfer platform established by KU Leuven and the European Investment Fund-and receives support from the Michael J. Fox Foundation.”


Ubigene Biosciences is co-founded by biological academics and elites from China, the United States, and France. We are located in Guangzhou Science City, which serves as a global center for high technology and innovation. Ubigene Biosciences has 1000㎡ office areas and laboratories, involving genome editing, cell biology technology, and zebrafish research. We provide products and services for plasmids, viruses, cells, and zebrafish. We aim to provide customers with better gene-editing tools for cell or animal research.

We developed CRISPR-U™ and CRISPR-B™ (based on CRISPR/Cas9 technology) which is more efficient than general CRISPR/Cas9 in double-strand breaking, CRISPR-U™ and CRISPR-B™ can greatly improve the efficiency of homologous recombination, easily achieve knockout (KO), point mutation (PM) and knockin (KI) in vitro and in vivo. 

Genome Editing Platform
——Focusing on the Application of CRISPR-U™ and CRISPR-B™ Gene Editing Technology
1. Provides various types of gene-editing vectors for different species.2. Provides different virus packaging services, including lentiviruses, adenoviruses and adeno-associated viruses.3. Provides high-quality services for gene knockout, point mutation and knockin cell lines. 

Cell Biology Platform
——Focusing on primary cell
1. Provides over 400 types of primary cells.2. Provides culture strategies and related products for different cell types.3. Provides cell biology-related services such as cell isolation, extraction and validation.